News

Conference Coverage

Optimal Botensilimab and Balstilimab Dose for Refractory Microsatellite Stable Colorectal Cancer

02/11/2025

Marwan Fakih, MD

Marwan Fakih, MD, discusses study results which identified the optimal dosage of botensilimab and balstilimab for patients with refractory microsatellite stable colorectal cancer without liver metastases.

Marwan Fakih, MD, discusses...

02/11/2025

Oncology

Videos

Nivolumab Plus Ipilimumab Combination for Microsatellite Instability-High, Mismatch Repair-Deficient Metastatic Colorectal Cancer

02/04/2025

Thierry André, MD

Thierry Andre, MD, describes results from the CheckMate 8HW trial which evaluated nivolumab plus ipilimumab compared with nivolumab monotherapy among patients with MSI-H/dMMR metastatic colorectal cancer.

Thierry Andre, MD, describes...

02/04/2025

Oncology

Conference Coverage

Amivantamab With or Without Chemotherapy for Right-Sided Metastatic Colorectal Cancer

01/28/2025

Filippo Pietrantonio

Filippo Pietrantonio, MD, discusses updated results from the phase 1b/2 OrigAMI-1 trial, which showed that amivantamab with or without chemotherapy demonstrated durable antitumor activity among patients with right-sided metastatic colorectal...

Filippo Pietrantonio, MD,...

01/28/2025

Oncology

Anna Martling, MD, Karolinska Institutet

Videos

Aspirin Reduced Risk of CRC Recurrence for Patients With PI3K Alterations

01/28/2025

Anna Martling, MD, PhD, discusses study results which found that adjuvant daily aspirin reduced the risk of colorectal cancer recurrence among patients with PI3K alterations.

Anna Martling, MD, PhD,...

01/28/2025

Oncology

Conference Coverage

Association Between ctDNA and Disease-Free Survival Among Patients With Colorectal Cancer

01/28/2025

Allison Casey

Data from the BESPOKE CRC study found ctDNA to be prognostic of DFS within the molecular residual disease and surveillance windows among patients with stage II to stage III colorectal cancer.

Data from the BESPOKE CRC study...

01/28/2025

Oncology

Conference Coverage

Encorafenib Plus Cetuximab and Chemotherapy for BRAF V600E-Mutant Metastatic Colorectal Cancer

01/27/2025

Allison Casey

According to results from the BREAKWATER trial, encorafenib plus cetuximab and FOLFOX showed a significant improvement in response rate that was rapid and durable among patients with BRAF V600E-mutant metastatic colorectal cancer.

According to results from the...

01/27/2025

Oncology

Conference Coverage

Aspirin Reduces Risk of Colorectal Cancer Among Patients With PI3K Alterations

01/27/2025

Allison Casey

According to results from the ALASCCA trial, adjuvant daily aspirin treatment significantly reduced the rate of recurrence among patients with colorectal cancer with PI3K alterations.

According to results from the...

01/27/2025

Oncology

Conference Coverage

ctDNA Determines Prognosis, Celecoxib Benefit For Patients With Stage III Colon Cancer

01/27/2025

Allison Casey

According to data from the phase 3 CALGB/SWOG 80702 study, ctDNA may predict the benefit of adjuvant celecoxib to disease-free survival and overall survival for patients with stage III colon cancer.

According to data from the phase...

01/27/2025

Oncology

Conference Coverage

Nivolumab Plus Ipilimumab Potential New Standard of Care for Microsatellite Instability-High, Mismatch Repair-Deficient Metastatic Colorectal Cancer

01/27/2025

Allison Casey

According to results from the phase 3, CheckMate 8HW trial, nivolumab plus ipilimumab demonstrated superior PFS compared with nivolumab monotherapy for patients with microsatellite instability-high, mismatch repair-deficient metastatic...

According to results from the...

01/27/2025

Oncology

Conference Coverage

Co-Formulated Favezelimab And Pembrolizumab Fails to Improve Survival for Metastatic Colorectal Cancer

01/27/2025

Stephanie Holland

Results from the phase 3 KEYFORM-007 trial demonstrated that co-formulated favezelimab and pembrolizumab failed to significantly improve survival compared to standard of care among patients with PD-L1-positive. microsatellite stable or...

Results from the phase 3...

01/27/2025

Oncology

Recent News

News

Modakafusp Alfa Demonstrates Antitumor Activity Among Patients With Relapsed/Refractory Multiple Myeloma

04/02/2025

Emily Estrada

At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.

At a tolerable and safe dose,...

04/02/2025

Oncology

News

Quadruplet Therapy Demonstrates Efficacy for Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma

04/02/2025

Emily Estrada

Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.

Quadruplet therapy with...

04/02/2025

Oncology

News

Co-Occurrence of High-Risk Cytogenetic Abnormalities as a Predictive Marker for Multiple Myeloma

04/02/2025

Emily Estrada

The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.

The presence of 2 or more...

04/02/2025

Oncology

News

Pembrolizumab Plus Bevacizumab Shows Promise Among Previously Untreated Patients With Melanoma Brain Metastases

04/01/2025

Stephanie Holland

According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.

According to results from a...

04/01/2025

Oncology

News

Outcomes Without Adjuvant Radioactive Iodine Among Pediatric Patients With Papillary Thyroid Cancer

04/01/2025

Allison Casey

According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.

According to a retrospective...

04/01/2025

Oncology

News

Lenvatinib Plus High-Dose Radioiodine Therapy Shows Promise for Patients With Metastatic Well-Differentiated Thyroid Cancer

04/01/2025

Allison Casey

A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.

A study found the addition of...

04/01/2025

Oncology

News

Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors

03/31/2025

Janelle Bradley

Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.

Findings from a phase 2 study...

03/31/2025

Oncology

FDA Approval

Durvalumab Approved for Muscle Invasive Bladder Cancer

03/31/2025

Allison Casey

The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.

The US FDA approved neoadjuvant...

03/31/2025

Oncology

FDA Approval

FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer

03/28/2025

Stephanie Holland

Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...

Based on results from the...

03/28/2025

Oncology

FDA Approval

FDA Approves Cabozantinib for Patients With Locally Advanced or Metastatic Well-Differentiated pNETs and epNETs

03/26/2025

Stephanie Holland

Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...

Based on results from the...

03/26/2025

Oncology